Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Apixaban · Eliquis

Small molecule · Inhibitor of Factor Xa (F10) · developed by Bristol Myers Squibb

Approved FDA, Dec 2012

BMY Developer

1 Registered trials

What is Apixaban?

Apixaban is a selective inhibitor of Factor Xa that decreases thrombin generation and thrombus development. It inhibits both free and clot-bound FXa and indirectly inhibits platelet aggregation induced by thrombin.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Eliquis
Drug type: Small molecule
Targets: Factor Xa (F10)
Mechanism: Inhibitor of Factor Xa (F10)
Pathways: thrombin generation, thrombus development
Therapy area: Cardiovascular
Developer: Bristol Myers Squibb (BMY)
FDA status: Approved as Eliquis (December 28, 2012), NDA202155 · FDA label

✅ FDA-approved uses

Reduction of risk of stroke and systemic embolism in nonvalvular atrial fibrillation
Prophylaxis of deep vein thrombosis following hip or knee replacement surgery
Treatment of deep vein thrombosis
Treatment of pulmonary embolism
Reduction in risk of recurrent deep vein thrombosis and pulmonary embolism
Treatment of venous thromboembolism in pediatric patients

From the indications section of the FDA label (version of Apr 24, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05757869	Phase 3	Atrial Fibrillation	Active not recruiting	BMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Atrial Fibrillation

More from Bristol Myers Squibb

Belatacept FDA approved Deucravacitinib FDA approved Ipilimumab FDA approved Lisocabtagene Maraleucel FDA approved Luspatercept FDA approved Mavacamten FDA approved Nab-paclitaxel FDA approved Nivolumab FDA approved Ozanimod FDA approved Relatlimab FDA approved Repotrectinib FDA approved Xanomeline FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BMY page.

Follow BMY, the company behind Apixaban

See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z